The global CRISPR & Cas Genes market size is expected to reach USD 4.75 billion by 2027 according to a new study by Polaris Market Research. The report “CRISPR & Cas Genes Market Size, Share & Trends Analysis Report, By Product & Service (Product {Kits & Enzymes, Libraries, Design Tool, Antibodies, and Others}, and Service {Cell Line Engineering, gRNA Design, Microbial Gene Editing, and DNA synthesis); By Application (Biomedical and Agricultural), and By End Use (Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations (CROs)), and Segment Forecasts, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
CRISPR refers to a gene editing tool through which the biological researchers and scientists can modify the genomes of various living creatures. The CRISPR technique relies on the antiviral defense mechanism of the bacteria-based CRISPR-Cas9 system. The synthetically created guide RNA is being complexed with Cas9 nuclease and delivered into the cell. Through this technique, the genome of cells can be sliced at any desired location while enabling the removal of available genes or/and adding novel genes in vivo.
Download Sample Copy: https://www.polarismarketresearch.com/industry-analysis/crispr-associated-cas-genes-market/request-for-sample
The Cas9 nuclease acts as a genetic scissor and used to open both the strands of specific DNA sequence for introducing the desired modification through the deployment of any one of the two techniques. These techniques include knock-in mutations which is enabled through the Homology Directed Repair (HDR) and via Non-Homologous End Joining (NHEJ).
The prominent factors favoring the CRISPR & CRISPR-Associated (Cas) genes market growth include technological advancement in gene editing platform and launch of various anti-CRISPR proteins that are expected to improve the overall accuracy of CRISPR technique. SpCas9-HF and eSpCas9 are two novel versions of Cas9 protein that have been designed in laboratory for minimizing the editing activity which is off the target without any use of sgRNAs.
According to the American Association for the Advancement of Science (AAAS) February 2020 release, the researchers have integrated two techniques viz. T cell therapy, which exploits the sentry of the body’s immune system for destroying tumors and CRISPR, which is used for editing of DNA. The researchers have found the advanced CRISPR gene editing tool to be very safe when used on three patients suffering from cancer.
Do you have questions or special requirements? Ask our industry experts : https://www.polarismarketresearch.com/industry-analysis/crispr-associated-cas-genes-market/speak-to-analyst
According to the Stat News February 2019 publication, China’s Science Ministry along with two other government institutions in the country are expected to have funded a study referred to as “CRISPR babies”. This study has resulted in the birth of two genetically altered twin girls in November 2018 in China. Therefore, the biological researchers have successfully achieved a key technique to start pregnancy among humans through the deployment of CRISPR Cas9 gene editing tool on human embryos.
Companies such as Addgene, AstraZeneca, Caribou Biosciences, Inc., Cellectis, Cibus, CRISPR Therapeutics, Danaher Corporation, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd., Genscrip, Horizon Discovery Group Plc, Lonza, Mammoth Biosciences, Merck KGaA, New England BioLabs, Synthego, and Takara Bio, Inc. are some of the key players operating in the clustered regularly interspaced short palindromic repeats (CRISPR) & CRISPR-associated (Cas) genes market.
Players in the market are focusing on adopting CRISPR & Cas gene editing technology for engineering the blood stem cells and immune cells as a key tool being deployed for enabling drug discovery while creating highly targeted anticancer drugs. Additionally, in May 2020, the U.S. Food and Drug Administration (FDA) has approved the CRISPR-based diagnostic kit for testing of the SARS-CoV-2 COVID-19 coronavirus in laboratory. According to the Nature Journal May 2020 publication, the U.S. has already increased the COVID-19 testing while averaging about 250,000 COVID-19 test per day. The rapid FDA approval to the test kits is expected to boost testing, reducing backlogs.
Polaris Market Research has segmented the CRISPR & Cas Genes market report on the basis of product & service, application, end-use, and region
